This BSA for AD follows the original description of a BSA formed by fusion of a single chain Fv (ScFv) antibody directed at the Abeta peptide of AD to the carboxyl terminus of either a MAb against the human insulin receptor (HIR), designated HIRMAb [90], or to a MAb against the mouse TfR, designated the TfRMAb [98]. This evidence concerns the gene INSR and Alzheimer disease.